Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cue Biopharma (CUE) Capital Expenditures (2017 - 2025)

Cue Biopharma (CUE) has disclosed Capital Expenditures for 8 consecutive years, with $27000.0 as the latest value for Q2 2025.

  • Quarterly Capital Expenditures rose 170.0% to $27000.0 in Q2 2025 from the year-ago period, while the trailing twelve-month figure was $177000.0 through Dec 2025, up 168.18% year-over-year, with the annual reading at $177000.0 for FY2025, 168.18% up from the prior year.
  • Capital Expenditures hit $27000.0 in Q2 2025 for Cue Biopharma, down from $150000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $648000.0 in Q1 2021 to a low of -$1000.0 in Q3 2024.
  • Historically, Capital Expenditures has averaged $94788.5 across 4 years, with a median of $27000.0 in 2022.
  • Biggest five-year swings in Capital Expenditures: tumbled 99.96% in 2021 and later soared 2464.1% in 2022.
  • Year by year, Capital Expenditures stood at $39.0 in 2021, then skyrocketed by 2464.1% to $1000.0 in 2022, then surged by 100.0% to $2000.0 in 2024, then skyrocketed by 1250.0% to $27000.0 in 2025.
  • Business Quant data shows Capital Expenditures for CUE at $27000.0 in Q2 2025, $150000.0 in Q1 2025, and $2000.0 in Q4 2024.